Staging of neurodegenerative diseases is based chiefly on the topographical or anatomical extent of aggregated proteinaceous inclusions, and the density or severity of the lesions in a given region usually assessed semiquantitatively. Associated phenomena, such as cell loss and synapse loss, are evaluated but not staged. This article reviews the development of neuropathological staging of the sporadic Alzheimer's and sporadic Parkinson's diseases. It considers challenges for staging systems, and it poses the question whether neuropathological staging as practiced up to now is still relevant.
Introduction
The internationally recognized classification system (Union Internationale Contre le Cancer, UICC), which is updated every six to eight years within the context of an ongoing joint effort between the UICC and the American Joint Committee on Cancer to include the latest advances in oncology, has long been used to characterize malignant tumors [1] [2] [3] [4] . The UICC TNM Classification of Malignant Tumours system combines 'grading' (tumor differentiation as an index of aggressiveness) and 'staging' (anatomical extent of disease) with a view toward predicting outcomes (prognoses) and optimizing therapies.
In contrast to this, staging of conformational diseases (proteinopathies) [5, 6] associated with neurodegenerative diseases [7] , such as Alzheimer's disease (AD) and Parkinson's disease (PD), was a relatively late development, beginning in the 1990s, and no truly internationally collaborative setting exists whereby the different staging systems currently in use can be discussed, so that neuropathological staging guidelines can be updated worldwide in light of the most recent advances.
This article reviews the development of neuropathological staging of sporadic AD and sporadic PD, challenges and advantages of staging systems, and it poses the question whether neuropathological staging as practiced up to now is still relevant.
Neuropathological staging Del Tredici and Braak 11 . The proposed topographical distribution pattern in AD is depicted cumulatively, using different shading for each phase: Isolated Ab plaques in one or more regions of the basal temporal and the orbitofrontal neocortex (phase 1); additionally, plaques in the allocortex, amygdala, and nearly all high order association areas of the neocortex (phase 2); expansion into secondary neocortical fields and into the striatum (phase 3); plaque formation in nearly all areas of the neocortex and in the midbrain -above all, the inferior colliculi (phase 4); plaque formation in the lower brainstem and in the cerebellum. Current in vivo amyloid imaging PET cannot detect the progression associated with phases 4 and 5.
structures, by the modified Gallyas silver-iodide method or thiazin red staining [28] . Additionally, it was seen that, ultrastructurally, the filaments consisted of tau in a crossb configuration [29] . In 2006, the original staging procedure for NFTs/NTs was revised for routine use based on AT8 immunohistochemistry rather than Gallyas staining [30] . Further, staging of Ab deposition (not including neuritic plaques) was expanded to five phases so as to include not only the deposits in the cerebral cortex but also those in subcortical regions and the cerebellum [31 ] ( Figure 2b ): In that study, silver stains and 4G8 immunohistochemistry were used. Once again, clinicopathological correlations were not performed. [62] . Were the tau pathological process to cease developing at some point, as suggested by the PART hypothesis, the neuropathologist should see only argyrophilic NFTs/NTs and tombstone tangles during stages I-IV in the absence of or with a reduction of new or 'fresh' tau lesions, namely, the non-argyrophilic pretangles, thereby implying that NFT/NT formation would have ceased. On the contrary, pretangle formation persists even during NFT stage VI, that is, the tau pathological process does not, contrary to Ab deposition, stop or 'burn out' in end-stage AD [47, 49] . Support for the idea that NFT stages I-III with Ab deposition phase 0 ('definite PART') likely belong to a pathobiological continuum with progression to more advanced disease stages of AD accompanied by Ab deposition rather than being non-AD-related comes from a recent study, which found that 'definite PART' cases were associated with cognitive slowing possibly related to hippocampal atrophy [63] . Thus, PART seems to unnecessarily truncate the staging system in the absence of new genetic, molecular, or morphological evidence about the neuropathological substrate of preclinical AD.
Neuropathological staging of sporadic Parkinson's disease
As in the AD field, postmortem staging of Lewy pathology in Parkinson's disease (PD) evolved within a larger framework of earlier groundbreaking genetic and biochemical research, including the discovery of pathogenic a-synuclein gene mutations in a subset of familial PD pedigrees [64, 65] and the finding that the presynaptic protein a-synuclein is a major constituent of Six stages of idiopathic Parkinson's disease [73 ,79,91] . The proposed regional distribution pattern of the lesions is depicted using degrees of shading for each stage. [66 ,67] . It was also shown that triplication of the SNCA gene causes a rapidly progressing form of PD [68] in contrast to SNCA gene duplication, which is associated with a later age of onset and slower disease progression [69] [70] [71] [72] .
The first attempt to define different neuropathological stages of Lewy pathology in sporadic PD [73 ] was based, as in 1991, on the observation that the topographical extent of the brain lesions is non-random and consistently develops in specifically vulnerable areas, cell lamina, and neuronal types [74 ,75-78] . In addition, the proposed staging procedure rested upon the assumption that the pathological process in sporadic PD progresses from beginning to end according to a uniformly characteristic sequence [73 ,79] . Cases with diffuse Lewy body disease (dementia with Lewy bodies, DLB) were expressly excluded [73 ,79-81] . The system delineated six stages of disease progression and, although the severity of the lesions in earlier involved regions was generally seen to increase during subsequent PD stages, a grading system for the lesions was not proposed (Figure 3 ). Importance was assigned to neuronal loss in the locus coeruleus and pars compacta of the substantia nigra [73 ,75,79,82] . Clinicopathological correlations were not performed as part of the initial staging effort. Later, the system was expanded to include the lesions in the spinal cord [83] .
Different groups of evaluators subsequently shortened [84] , modified, or refined it for use in routine neuropathology [46 , 85, 86 ] . Somewhat less prominent in the 2012 recommended guidelines [46 ] than in the original PD staging system was one of the central assumptions that had also been important for staging AD, namely, that 'incidental Lewy pathology' (ILBD) detected in asymptomatic individuals can represent prodromal PD [79,86 ,87-90] .
The 2003 staging system for Lewy pathology in sporadic PD is widely used [52, [91] [92] [93] [94] [95] [96] [97] , but both the concept of a uniform caudorostral trajectory of progression through the lower brainstem [86 ,98-100] as well as the idea that Lewy pathology may progress by 'spreading' in the brain along anatomic connectivities, as originally proposed for PD and tested in some animal models, have been questioned: For instance, why do regions receiving strong efferents from the pars compacta of the substantia nigra (the nigral pars reticulata, globus pallidus, subthalamic nucleus) remain uninvolved [101] ? The idea that specific regions and cell types are selectively vulnerable to the slowly progressing pathological process in PD [79, [101] [102] [103] is not inevitably incompatible with the concept of transneuronal retrograde axonal transport along anatomical connectivities [104, 105] : Inasmuch as axons projecting to the pallidum and subthalamic nucleus undergo myelination early they may be better protected against the lesions than unmyelinated or incompletely myelinated projections [102] . Also, of note, there is no autopsy-based evidence that, in either ILBD or PD, cases exist in which the pars compacta of the substantia nigra is the only region showing Lewy pathology or, conversely, that the lesions develop in all vulnerable brain regions with the same density simultaneously [73 ,86 ,100,106,107] .
Challenges for neuropathological staging systems
'Staging of cancer is not an exact science.' [108] Because neurodegenerative disorders are not pathobiologically static processes but possess a dynamic of their own, neuropathological staging procedures are, de facto, artificial constructs. At the same time, a high degree of simplicity and reproducibility is demanded to reliably classify the pathological process in question for effective inter-laboratory comparisons of results.
It can be challenging to define precise cut-off points, that is, the extent of the most typical lesions between proposed stages, for pathological states that are in 'transition' [30, 44 ] . In addition, in PD, staging is complex because a larger number of brain regions generally are sampled than in AD to assign a stage [46 , 73 ,85,86 ,100] , and, at least in a research context, it is important to include tissue from the spinal cord, enteric, and peripheral nervous system [83, 106] . Tissue from these regions and from the olfactory bulb, however, are not always available because the bulb is often avulsed during autopsy. Further, although the amplification of the a-synuclein gene in familial forms of PD with Lewy pathology are strong indicators that the lesions are pathogenic, scientists are divided over whether the intracellular a-synuclein aggregates, Lewy bodies and Lewy neurites, are just as important pathological markers for PD staging as neuronal loss [79,86 ,109,110] .
Fundamental factors that influence the applicability of existing staging systems for AD and PD include setting (e.g. routine neuropathology versus a research context) and study design (e.g. population-based, communitybased, clinic-based, referral-based cohorts, retrospective versus prospective/longitudinal studies) [96, 100, 107, 111] . The choice and number of anatomic regions sampled (or considered necessary for characterizing each stage), differences in section thickness (e.g. 5À10 mm or 70À100 mm), different methods of tissue processing (choice of antibodies and antibody retrieval), and different staining protocols (automated strainers versus staining free-floating) all account for variability in inter-observer assessment and can produce discrepant results [30,44 ,73 ,79,85,100,112,113] . For example, NFT/NT stage I cases are assigned somewhat more frequently when using AT8-immunostained rather than Gallyasiodide stained sections because AT8-positive nerve cells are not argyrophilic in the early phase of AD. As such, NFT/NT staging needs to be performed using either AT8 (or thioflavin S) immunohistochemistry or silver staining, but not both AT8 and the Gallyas method [30, 46 ] .
In AD staging, an additional difficulty appears to be a lack of familiarity with the neuroanatomy of the anterior portion (mid-uncus) of the hippocampus, which may in turn be attributable to the fact that for routine neuropathology in 5À10 mm sections the only hippocampal sample usually taken is from the posterior (Ammon's horn) hippocampus at the level of the geniculate body: The latter sample, however, does not include the transentorhinal region that is essential for assessing NFT/NT stages I-III [30,44 ,51 ] (Figure 1b) .
A widespread phenomenon encountered during staging is the existence of multiple or concomitant pathologies, including cerebrovascular changes [24, 52] . Depending on the composition and size of the cohorts studied [59 , 107, 111, [114] [115] [116] , up to 63% of cases displayed mixed pathologies [117] . Although they have not yet been independently validated, neuropathological staging systems based on the anatomic extent of the lesions have also been proposed for pathologies associated with AD: These include argyrophilic grain disease, a 4R tauopathy in the medial temporal lobe with extension into other related limbic structures [118] , and TDP-43 proteinopathy [119, 120] .
Some proteinopathies with predominantly glial pathologies (e.g. progressive supranuclear palsy, multiple system atrophy) still virtually defy neuropathological staging based on an anatomic extent of the lesions, and the correlation of the characteristic lesions with clinical data remains complex [121] [122] [123] . Pathological and clinical variations also have been described that are not stageable using any of the available protocols [124] .
Finally, a collaborative setting is needed whereby the different neuropathological staging systems currently in use can be discussed and harmonized by acknowledged experts with the goal of regularly updating staging guidelines in view of the latest advances and problems. Such a venue must be genuinely conducive to broad international participation and debate [125] , which is possible in the age of virtual microscopy, and it could be useful for establishing an AD grading system, that is, based on neuronal loss and the ratio between involved nerve cells and tombstone tangles, to assess the aggressiveness of the pathological process
Is neuropathological staging obsolete?
Here, it may be helpful once more to consider the lessons learned and insights gained from colleagues in the field of oncology:
'A major challenge to TNM staging is the rapid evolution of understanding in cancer biology and the availability of biologic factors that predict cancer outcome and response to treatment with better accuracy than purely anatomically-based staging. This has led some cancer experts to conclude that TNM is obsolete. Although such statements are misguided, the reality is that the anatomic extent of disease only tells part of the story . . . . The question of including non-anatomic prognostic factors in staging has led to intense debate about the purpose and structure of staging . . . . In the future, the discovery of new markers will make it necessary to include these markers in staging and will likely require the development of new strategies beyond the current grouping systems. That said, it must also be clearly stated that it is critical to maintain the anatomic base to cancer staging. Anatomic extent of disease remains the key prognostic factor in most diseases' [2] Fluid biomarkers [126] [127] [128] and modern in vivo neuroimaging [129] [130] [131] [132] [133] are powerful and promising diagnostic tools [134] that are minimally invasive, but they will not replace neuropathological confirmation within the context of cross-sectional and longitudinal autopsycontrolled studies: Pathoanatomic correlation with biomarker and with imaging modalities is always needed not only to control for mistaken clinical diagnoses and the presence of concomitant neurodegenerative proteinopathies [52, 135] but also to help generate and/or test new neuropathological staging systems and new proposed guidelines for neurodegenerative disorders [125, 136, 137] , novel disease models [79, [138] [139] [140] , and new hypotheses about pathogenesis or therapies.
Conclusion
The anatomic extent of the defining pathologies characterizing neurodegenerative diseases is currently the primary basis for neuropathological staging and postmortem confirmation the gold standard [94] , thereby making the decline in autopsy rates and autopsy-based neuropathology an ongoing cause for concern [7,141]. In the future, it can be anticipated that pathobiologic markers together with discoveries and correctives from the fields of biochemistry, in vivo neuroimaging, and genetics [142] will continue to expand the spectrum of non-anatomic, including molecular, factors applicable to neuropathological staging with a view toward more individualized diagnostic profiling [52] , as is already the case in cancer staging [143] . This study was the first to isolate two monoclonal antibodies, AT8 and AT10, which showed no crossreactivity with normal tau in Western blot and ELISA. Of these two, only AT8 showed complete specificity in situ by immunocytochemistry. Both antibodies were directed against phosphatase-sensitive epitopes, thereby providing additional evidence that abnormal phosphorylation is a major modification in the tau proteins incorporated in paired helical filaments. A retrospective study and semiquantitative classification of the topography and progression of brain Ab deposits performed on AD (N = 17) and nondemented (N = 9) cases. The authors proposed a revised and expanded staging system consisting of five phases intended to replace the three stages A-C originally proposed in Ref. [12] . Campbell-Switzer pyridine silver staining and 4G8 immunohistochemistry were carried out on free-floating tissue sections of 100 mm thickness. [12] as semiquantitatively assessed by AT8 immunohistochemistry, thioflavin S dye, or sensitive silver staining, for example, the modified Gallyas-iodide method (B), and a Consortium to Establish a Registry for Alzheimer Disease (CERAD) neocortical neuritic plaque score (C). Like its predecessor [50], these guidelines expressly recognized the evidence that the AD neuropathological process is a continuum (preclinical stage, MCI, dementia) that begins in asymptomatic individuals decades before the onset of cognitive symptoms. A drawback is that only two of the authors on the panel were working in Europe, and there were no invited contributors from Asia or outside North America. Similarly, CERAD, consisting of 32 neuropathologists from fifteen reference centers in the United States, provided neuropathologic definitions of the terms 'definite Alzheimer's disease' (AD), 'probable AD,' 'possible AD,' and 'normal brain,' and semiquantitatively evaluated only neuritic plaques [24] in at least eight standardized brain regions using paraffin sections stained with Bielschowsky or Gallyas silver stains or thioflavin S dye. Tissue was available from demented individuals (N = 142) clinically diagnosed as 'probable AD' and in N = 8 nondemented cases.
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